Billets de Michelle Dawson

Billet publié sur Twitter/X le 24/07/2021 12:24

Twitter/X Essai clinique clinicaltrials.gov Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Centre for Addiction and Mental Health (2021). rTMS for Depression in Young Adults With Autism. ClinicalTrials.gov. Centre for Addiction and Mental Health.

Date de publication
14/01/2021
Identifiant
NCT04972136
Auteurs
Centre for Addiction and Mental Health
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Centre for Addiction and Mental Health
Source de métadonnées
clinicaltrials.gov

Résumé

The current clinical trial is focused on evaluating the efficacy of rTMS for treatment of depression in youth and young adults (hereafter called transition aged youth, TAY) with autism spectrum disorder (ASD). The motivation to undertake the current efficacy study is driven by: (1) the substantial impact of depression on TAY with ASD (based on prevalence and contribution to disability/impairment); (2) lack of evidence-based treatments for depression in autism (there are no current trials rigorously evaluating any treatment for depression, i.e., psychotherapeutic, pharmacotherapeutic, brain stimulation); (3) rTMS has demonstrated efficacy in non-autistic individuals to improve symptoms of depression and may be better tolerated in youth than medication treatment; (4) a prior pilot rTMS study focused on treatment of executive function deficits in autism indicated that high frequency rTMS delivered using a rigorous randomized control trial (RCT) protocol can be feasibly implemented in TAY with autism, is well tolerated (mild to moderate adverse effects and low drop out), and has the potential to improve symptoms of depression.